Investor Presentation H1 2023
65
Investor presentation
First six months of 2023
In STEP 1, people treated with semaglutide had a superior
weight loss of up to 16.9%
The pivotal STEP 1 trial showed greater than 16% weight loss
% change in
body weight
Data from STEP 1
0
-4
-8
-12
-16
•
Average age 46
.
Placebo: -2.4%
74.1% women
•
Average BMI 37.9 kg/m²
Improvements in lipid profile as well as
C-reactive protein
Semaglutide 2.4 mg: -16.9%
Semaglutide improved health-related
quality of life as measured by SF-36 and
IWQOL-lite-CT
-20
0 4 8 12 16 20
28
36
44
52
60
68
Time since initiation (weeks)
Change in body weight in % depicts observed means since time of randomisation; trial product estimand.
BMI: body mass index; SF-36: Short Form (36) Health Survey; IWQOL-lite-CT: Impact of Weight on Quality of Life-Lite questionnaire
Novo NordiskⓇView entire presentation